HBV'de Tedavi - EKMUD

Biyolojik Ajanlarla Tedavi:
Biyolojik Ajanların Yapısı ve Etki Mekanizması
beraberinde getirmiştir. Bu yan etkiler biyolojik
tedavinin uygulanma zamanı ve dozuna bağlı
olarak değişebilmektedir. İmmünmodülatör
ilaçları kullanan hastaların olası yan etkiler
yönünden dikkatli izlenmesi gerekmektedir.
KAYNAKLAR
1. Ahmed S, Anolik JH. B-cell biology and related therapies
in systemic lupus erythematosus. Rheum Dis Clin North
Am 2010;36:109-30.
2. Antonarakis ES, Drake CG. Current status of immunological
therapies for prostate cancer. Curr Opin Urol
2010;20:241-6.
3. Bringmann A, Erika Held SA, Heine A, Brossart P. RNA
vaccines in cancer treatment. Journal of Biomedicine and
Biotechnology 2010;ID:623-87.
4. Davis J, Wofsy D. Immunomodulators. In: Parslow TG,
Stites DP, Terr AI, Imboden JB (eds). Medical Immunology.
10 th ed. New York: Mc Graw-Hill Companies, 2001:757-
60.
5. Dilillo DJ, Horikawa M, Tedder TF. B-lymphocyte effector
functions in health and disease. Immunol Res 2010. DOI:
10.1007/s12026-010-8189-3.
6. Ehrenstein MR, Notley CA. The importance of natural
IgM: scavenger, protector and regulator. Nat Rev Immunol
2010;10:778-86.
7. Gabay C, McInnes IB. The biological and clinical importance
of the “New Generation” cytokines in rheumatic
diseases. Arthritis Research & Therapy 2009;11:1-14.
8. Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G,
et al. MS-SIN Study Group. Natalizumab therapy of multiple
sclerosis: recommendations of the Multiple Sclerosis
Study Group-Italian Neurological Society. Neurol Sci
2011. DOI: 10.1007/s10072-010-0469-0.
9. Bartlett JB, Battiwalla M, Chanan-Khan A, et al.
Immunomodulatory drugs: The emerging treatment
paradigm for hematologic malignancies highlights from a
symposium held during the 10 th congress of the European
Hematology Association which took place on thursday,
2005, Sweden.
10. John LR. B cell-targeted therapies for systemic lupus erythematosus:
an update on clinical trial data. Drugs
2010;70:529-40.
82
11. Kathleen Hawker. B cells as a target of immune modulation.
Ann Indian Acad Neurol 2009;12:221-5.
12. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA.
Mesenchymal stem cells: immunobiology and rolein
immunomodulation and tissue regeneration. Cytotherapy
2009;11;4:377-91.
13. La Cava A. Anticytokine therapies in systemic lupus erythematosus.
Immunotherapy 2010;2:575-582.
14. La Cava A. Targeting B cells with biologics in systemic
lupus erythematosus. Expert Opin Biol Ther 2010;10:
1555-61.
15. Maloney D, Levy R, Miller R. Monoclonal anti-idiotype
therapy of B cell lymphoma. Biol Ther Cancer 1992;2:
1-10.
16. Mitsiades N., Mitsiades CS, Poulaki V, et al. Apoptotic
signaling induced by immunomodulatory thalidomide
analogues in human multiple myeloma cells: therapeutic
implications. Blood 2002;99:4525-30.
17. Notley CA, Ehrenstein MR. The yin and yang of regulatory
T cells and inflammation in RA. Nat Rev Rheumatol
2010;6:572-7.
18. Reang P, Gupta M, Kohli K. Biological Response Modifiers
in Cancer. From Medscape General Medicine.
19. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat
Rev Rheumatol 2010;6:326-37.
20. Shlomchik MJ. Activating systemic autoimmunity: B’s, T’s,
and tolls. Curr Opin Immunol 2009;21:626-33.
21. Thouvenot E, Hillaire-Buys D, Bos-Thompson MA, Rigau
V, Durand L, Guillot B, et al. Erythema nodosum and
glatiramer acetate treatment in relapsing-remitting multiple
sclerosis. Mult Scler 2007;13:941-4.
22. Tili E, Michaille JJ, Costinean S, Croce CM. MicroRNAs,
The immune system and rheumatic disease. Nat Clin
Pract Rheumatol 2008;4:534-41.
23. Yan Q. Immunoinformatics and systems biology methods
for personalized medicine. Methods Mol Biol 2010;
662:203-20.
24. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis
inhibitor with efficacy in colorectal and other malignancies.
Ann Pharmacother 2004;38:1258-64.
3. Türkiye EKMUD Bilimsel Platformu